Peptide profile · Cognitive
Cerluten
Brain-derived peptide bioregulator complex containing AED, KED, AEDG, and KE peptides that promote neurogenesis through histone binding, restore dendritic spine architecture under neurotoxic conditions, and enhance cognitive recovery in stroke and brain injury patients
Molecular formula
C11H17N3O8 (representative primary component)
- CAS number
- 75007-24-8
- PubChem
- 194641
- Developed · 1990s-2000s (based on brain peptide extract research beginning in the 1980s)
- Vladimir Khavinson, Saint Petersburg Institute of Bioregulation and Gerontology, Russia
Amino acid sequence
Multi-peptide complex: AED (Ala-Glu-Asp), KED (Lys-Glu-Asp), AEDG (Ala-Glu-Asp-Gly), KE (Lys-Glu) — composition: 50.7% tripeptides, 23.2% dipeptides, 22.1% tetrapeptides, 3.3% free amino acids, 0.7% pentapeptides1-2 capsules (0.2 g each)
Every documented dose level
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| 30-day intensive course; then 10-day maintenance course every 3 months | 1-2 capsules (0.2 g each) | 1-2 times daily with meals | Oral |
| Days 10-30 | 5-6 drops | 3-4 times daily under the tongue | Sublingual |
Best for cognitive recovery following stroke or traumatic brain injury & neuroprotection against age-related cognitive decline and neurodegeneration
Best for
Cognitive recovery following stroke or traumatic brain injury
Cerluten is particularly well-suited for individuals focused on cognitive recovery following stroke or traumatic brain injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection against age-related cognitive decline and neurodegeneration
Cerluten is particularly well-suited for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting neurogenesis and neuronal repair in aging brain tissue
Cerluten is particularly well-suited for individuals focused on supporting neurogenesis and neuronal repair in aging brain tissue. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive bioregulatory approach to brain aging using multiple complementary peptide components
Cerluten is particularly well-suited for individuals focused on comprehensive bioregulatory approach to brain aging using multiple complementary peptide components. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
- Known hypersensitivity to peptide bioregulators or bovine-derived products
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active CNS infection — treat infection before initiating peptide bioregulator therapy
- Prion disease concerns — although manufacturing processes include purification to remove proteins > 5 kDa, individuals with heightened prion risk should exercise caution
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Cerluten use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Cerluten with similar peptides to find the best fit for your goals.
Route
Cerluten is administered Oral (capsule)—no injection required
Best sites
- Not applicable—this is not an injectable formulation
The Cerluten dosing protocol covers how it is taken.
4 common side effects · 2 serious
Cerluten is a peptide extract from cerebral tissue of young animals that is not FDA-approved and lacks rigorous clinical safety data.
As an undefined mixture of peptides and proteins from animal sources, quality control and batch consistency cannot be guaranteed. Potential risks include allergic reactions to animal-derived proteins, contamination with microbial pathogens or prions, and unknown long-term immunological effects.
No comprehensive safety studies have been conducted in humans, and the active pharmaceutical components have never been identified or standardized. The product exists primarily in Russian and Eastern European medical markets without Western regulatory oversight.
Evidence consists of traditional clinical use in Russian medicine spanning decades and a small number of observational studies, primarily published in non-English journals. No toxicology screening, animal safety studies by modern standards, human Phase 1 data, or randomized controlled trials exist.
Published reports are mostly descriptive case series or open-label observations without proper controls or safety monitoring parameters.
Common side effects · experienced by some users
Mild headache
Transient headache during the initial days of treatment as brain neurochemistry adjusts to enhanced neuronal gene expression and modified signaling patterns.
Management
Ensure adequate hydration. Usually self-limiting within 3-5 days. Reduce dose temporarily if persistent.
Mild drowsiness
Slight fatigue or drowsiness in the first few days, particularly with the sublingual form, as neuronal activity patterns shift.
Management
Take in the morning or early afternoon. Usually resolves within the first week of use.
Mild GI discomfort
Slight nausea or stomach discomfort with oral capsule administration, common with peptide supplements.
Management
Take capsules with a small amount of food or water. Consider the sublingual form to bypass the GI tract.
Vivid dreams
Enhanced dream vividness reflecting active neuroplasticity and neural reorganization processes stimulated by the peptide complex.
Management
Generally benign and may indicate active neurogenesis. No action typically required.
Serious side effects
No documented serious adverse effects
Zero serious adverse events reported across all clinical studies (48+ patients) and 30+ years of Khavinson bioregulator use in over 15 million individuals. No withdrawal, drug dependence, or systemic toxicity documented.
Management
As with any supplement, discontinue and consult a healthcare provider if unexpected or severe reactions occur. Individuals with bovine protein allergies should use caution.
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cerluten
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cerluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- SafePinealon (EDR peptide — targeted serotonin/pineal support that complements Cerluten's broader neuronal peptide complex approach) — May be used together under medical guidance.
- SafeEpithalon/Epithalamin (AEDG peptide — supports melatonin synthesis and neuroendocrine function alongside Cerluten's cognitive effects) — May be used together under medical guidance.
- SafeCortexin (brain peptide preparation — complementary neurotrophic peptide complex with overlapping but distinct mechanisms) — May be used together under medical guidance.
With medications
- CautionOther CNS-active peptide complexes at high doses without medical guidance — potential for overlapping epigenetic effects — Use with caution—discuss with your healthcare provider.
- CautionStrong sedatives or CNS depressants — may produce additive sedation — Use with caution—discuss with your healthcare provider.
- CautionImmunosuppressive medications — Cerluten's component peptides have immunomodulatory properties that may interact with immunosuppression — Use with caution—discuss with your healthcare provider.
With supplements
- SafeMultivitamins — Generally safe to take alongside Cerluten. Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Limited human trials · first signs days 1-10
Evidence level
Limited human trials
60/100
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Cerluten is a natural mix of short peptides from cow brain that work like molecular switches to turn on genes for brain repair and growth.
It binds to the proteins that control your DNA, allowing new nerve cells to form and protecting against aging in brain cells. This helps improve thinking after stroke and slows age-related memory loss.
The deeper mechanism
Cerluten's peptide components modulate gene expression through epigenetic mechanisms involving direct interaction with histone proteins and DNA regulatory sequences.
The AEDG component forms specific complexes with histones H1/6 and H1/3 at defined DNA-interacting sites, increasing chromatin accessibility at promoter regions of neurogenic genes.
This increases transcription of nestin, GAP43, β-tubulin III, and doublecortin mRNA by 1.6-1.8 fold, promoting neuronal differentiation. The EDR component interacts with the DNA major groove, stabilizing dendritic spine architecture through caspase-3 inhibition.
The KED component stimulates IGF1 expression by 3.5-5.6 fold through activation of FOXO1 (longevity transcription factor) and modulation of TNKS2 (telomere maintenance) at nanomolar concentrations.
The AED component interacts with AT-rich DNA sequences in the minor groove, suppressing senescence markers (p16, p21, p53) while upregulating SIRT-6 (longevity-associated deacetylase).
All peptide components inhibit MMP-9 (tissue-degrading metalloproteinase), enhance Ki-67 and CD98hc (regeneration markers), and suppress caspase-dependent apoptosis, creating a synergistic multi-pathway approach to neuronal survival, regeneration, and anti-aging.
What to expect
Days 1-10
What you might notice
- Subtle initial changes — possibly slightly improved mental clarity or mood stability
- Mild side effects (headache, drowsiness) that resolve within the first few days
- Vivid dreams indicating early neural reorganization
- No dramatic cognitive changes expected yet — epigenetic mechanisms are building
What's normal
- Effects are subtle initially — the multi-peptide complex is working at the epigenetic level to alter gene expression through histone binding and DNA interaction
- Component peptides are beginning to upregulate neurogenic markers (nestin, GAP43) and anti-aging genes (SIRT-6, IGF1)
- Clinical studies showed EEG changes developing within the 10-20 day treatment period
What's next
- Continue the full treatment course — clinical benefits were observed at 10-20 days in studies
- Track any changes in memory, attention, or mental capacity for comparison
- The histone-peptide interactions initiated now will produce cumulative protein synthesis changes
Week 2-4
What you might notice
- Improved mental capacity and ability to focus on complex tasks
- Better memory function — both formation of new memories and recall of existing ones
- Enhanced attention span and reduced mental fatigue
- In post-stroke patients: measurable improvements in neurological function and MMSE scores
- Greater cognitive resilience under stress or demanding conditions
What's normal
- This is the therapeutic window where clinical studies demonstrated significant EEG normalization
- 64.6% of patients in the 48-patient study showed significant improvement in this timeframe
- Neurogenic markers (nestin, GAP43, doublecortin) should be upregulated, supporting new neuronal development
- Dendritic spine preservation mechanisms (EDR component) are actively protecting synaptic architecture
What's next
- Complete the full course duration (20-30 days for standard; 10-20 days for clinical protocol)
- Benefits will continue to develop after the course ends as structural neuroplastic changes mature
- Plan the next course in 3-6 months to reinforce and build upon the neurological improvements
Month 1-6 (inter-course period)
What you might notice
- Sustained cognitive improvements from persistent epigenetic changes and structural neuroplasticity
- Ongoing neuroprotective benefits from upregulated SIRT-6 and antioxidant pathways
- Neurogenesis-driven improvements may continue developing for weeks after the active course
- Benefits may gradually diminish over 3-6 months, indicating readiness for the next treatment course
What's normal
- Epigenetic modifications and structural neuronal changes persist beyond the active treatment period
- Khavinson bioregulator protocols are designed as cyclical treatments with 3-6 month intervals
- Long-term clinical follow-up (1-10 years) has shown sustained neurological benefits with repeated courses
- Each subsequent course reinforces and extends the benefits from previous treatments
What's next
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Cerluten over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
What is Cerluten and how does it differ from single-peptide bioregulators?
Cerluten is a natural peptide complex extracted from bovine cerebral cortex tissue, containing a mixture of ultrashort peptides including AED (Ala-Glu-Asp), KED (Lys-Glu-Asp), AEDG (Ala-Glu-Asp-Gly), and KE (Lys-Glu). Unlike single-peptide bioregulators such as Pinealon (one tripeptide) or Epithalon (one tetrapeptide), Cerluten provides multiple complementary peptide components that act through different but synergistic epigenetic mechanisms — histone binding, DNA major groove interaction, and DNA minor groove interaction — to produce broader neuronal effects. The composition is predominantly tripeptides (50.7%), with dipeptides (23.2%) and tetrapeptides (22.1%).
What clinical evidence supports Cerluten for brain conditions?
A clinical study at the Saint Petersburg Institute evaluated Cerluten in 48 patients with various CNS diseases including post-stroke (10 patients), craniocerebral injury (7 patients), vascular encephalopathies (5 patients), and decreased mental capacity (6 patients plus 20 with combination conditions). Treatment with 1-2 capsules 2-3 times daily for 10-20 days produced significant improvement in 64.6% and moderate improvement in 22.9% of patients, with enhanced brain bioelectric activity confirmed by EEG. A separate post-stroke study with 40 patients showed 18% improvement on MMSE cognitive scores and 22% increase in regional cerebral blood flow.
Is Cerluten safe given that it's derived from animal brain tissue?
Cerluten is manufactured through a purification process that removes all proteins above 5 kDa and eliminates foreign DNA, resulting in a mixture of only ultrashort peptides (2-5 amino acids) and free amino acids. These components are identical to peptides naturally produced in the human body. The 30+ year safety record across over 15 million patients in Russia and Eastern Europe shows no documented serious adverse effects, allergic reactions, drug dependence, or systemic toxicity. However, individuals with bovine protein allergies should exercise caution, and the theoretical concern of prion contamination — while addressed by the manufacturing purification process — should be noted.
How does the AEDG component in Cerluten promote neurogenesis?
The AEDG peptide (Ala-Glu-Asp-Gly, also known as Epithalon) promotes neurogenesis through a specific histone-binding mechanism. Molecular modeling shows it binds preferentially to histones H1/6 and H1/3 at defined DNA-interacting sites, altering chromatin accessibility. This leads to a 1.6-1.8 fold increase in mRNA expression of neurogenic differentiation markers including nestin (early neuronal marker), GAP43 (neuroplasticity protein), β-tubulin III (structural neuronal protein), and doublecortin (neuronal migration protein). These markers collectively indicate active neuronal differentiation from stem cells.
What is the recommended Cerluten cycling protocol?
The standard approach involves treatment courses of 10-30 days with intervals of 3-6 months between courses. For capsules: 1-2 capsules once daily before breakfast for 1-3 months per course. For sublingual drops: 5-6 drops 3-4 times daily for 1 month per course. Professor Khavinson recommended combining six bioregulators for 1-2 months twice yearly for comprehensive anti-aging: Endoluten (neuroendocrine), Vladonix (immune), Cerluten (brain), Sigumir (joints/bones), Svetinorm (liver), and Ventfort (blood vessels). Each subsequent course builds upon the epigenetic changes from previous treatments.
Can Cerluten help with post-stroke recovery?
Clinical evidence supports Cerluten's role in post-stroke cognitive recovery. In the 48-patient study, the 10 stroke patients showed significant improvements in mental capacity and neurological function. A separate 40-patient controlled study demonstrated 18% MMSE score improvement and 22% increased regional cerebral blood flow in the Cerluten group versus standard therapy alone. These findings suggest Cerluten can enhance standard rehabilitation when used as complementary therapy, though it should not replace established post-stroke treatment protocols.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Cerluten, on one page.
Cerluten dosing protocol